NIH selects LIAI for major study on allergy molecular causes and possible treatments

November 13, 2007

SAN DIEGO - (November 13, 2007) A major study that will provide a new window into understanding and potentially treating allergies will be conducted by the La Jolla Institute for Allergy & Immunology (LIAI) under a $5 million federal contract. The five-year study, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, could lead to revolutionary new approaches for treating allergies based on targeting T cells, white blood cells that regulate the immune response and which are some of the principal warriors in the body's defense.

LIAI, a nonprofit organization and one of the world's leading immunology research centers, will partner on the study with clinical researchers at the University of California, San Diego (UC San Diego) and the National Jewish Medical and Research Center in Denver, Colorado. Both centers will set up human subject protocols involving allergy sufferers who will donate blood for the LIAI study. "We are excited by this research partnership that directly connects the basic immunology science that LIAI is renowned for with the clinical work in patients at these two fine institutions," said LIAI's Alessandro Sette, Ph.D., principal investigator on the allergy contract.

The study will involve 200 donors over five years and will look at 32 common allergen sources, such as trees, grasses, weeds, fungi, mites, insects and mammals. Food allergies are not part of the study.

Howard Grey, M.D., project co-investigator, said the study will push knowledge of allergies to a deeper level. "The whole field has been dominated by the analysis of the antibody response, because that's what causes many of the symptoms of the disease - the sneezing, sniffling, coughing and so forth," he said, noting that the discovery of the immunoglobulin E (IgE) antibody in 1966 by Kimishige Ishizaka, M.D., Ph.D. and his wife, Teruko Ishizaka, Ph.D., who later helped launch LIAI, revolutionized allergy research.

"Now the scientific community has the tools to take our knowledge even further by analyzing T cell responses," he said. "It seems in keeping with our history that LIAI will now lead the next step - breaking down the allergy response to its most basic molecular level."

Results from the project will be available to scientists worldwide via the NIAID's Immune Epitope Database (IEDB), the world's largest research database on how the immune system responds to infectious diseases, allergens and other agents. The database, developed by LIAI under an NIAID contract, is a public health tool designed to speed the development of vaccines and treatments by sharing important research data with scientists around the globe.

Mitchell Kronenberg, Ph.D., LIAI president & scientific director, said the project is a perfect fit with LIAI because it is developing the IEDB. In addition, allergies are a cornerstone of its immunology-focused research activities. "Many people may not be aware that the immune system plays a role in so many diseases -- from cancer to infectious diseases," he said. "Allergies are no exception, and result from inappropriate or overactive immune responses." Kronenberg said the study also enables further collaboration between LIAI, now located in the new Science Research Park at UC San Diego, and the University's researchers.

Sette said the project will map down to the level of molecules and atoms the chemical structures recognized by the immune system and which cause it to initiate an allergic reaction. "This has the potential to directly impact all people who are afflicted with allergies, because it may lead to new, more effective ways of diagnosing and treating these diseases." According to the NIAID, allergic diseases affect as many as 40 to 50 million Americans, and they are among the major causes of illness and disability in the United States. Allergies can also lead to asthma, a respiratory disorder that accounts for one-quarter of all emergency room visits in the U.S. each year.

LIAI researchers will identify the specific allergy epitopes that cause T cells to launch an attack against the allergens. Epitopes are tiny sites on a protein or other molecule that instigate a T cell response. "This opens the possibility of developing therapies around those epitopes," Grey said. "There have already been some clinical trials which are showing promise with the approach of treating patients with allergy-related epitopes. The information we're developing will provide the clinical community with the ability to try this approach with a wide variety of allergic diseases."

Currently, many allergy sufferers receive desensitization treatments, whereby the patient is given increasing doses of the substance causing allergy or allergen over a long period of time in order to develop immune tolerance to the allergen. The approach can be problematic because patients already have antibodies to the allergens, which can cause reactions, and because it is also a very lengthy process. The idea behind the epitope-based therapies is that patients could be given small pieces or epitopes from the allergen that would be able to induce immune tolerance, without instigating an antibody reaction, Sette explained. If this proves true, it could produce the same effects as the current desensitization therapies, but in a much shorter period of time, and without the allergic side effects. "You would be desensitizing the cells (with the allergy epitopes), rather than activating them," he added.

Another important aspect of the research is analyzing the effects of regulatory T cells in the allergy process. This T cell type, which has only been discovered in the last decade, appears to suppress T cell reactions to allergens, rather than cause them. "We are hoping to find specific epitopes that activate these regulatory T cells," said John Sidney, project co-investigator. "If so, we might have an extremely powerful tool for treating allergy diseases."

LIAI's project efforts will be accelerated through bioinformatics along with the use of the allergy epitope information already in the IEDB. Bioinformatics uses computer databases, algorithms and statistical techniques to analyze biological information. "We developed the IEDB and we're going to take advantage of that huge resource to improve our epitope identification algorithms based on that data," said Bjoern Peters, Ph.D., project co-investigator. "We'll use those algorithms to statistically determine which allergy epitopes are most likely to trigger a T cell response and then test those assumptions in the lab. By using bioinformatics, we will greatly speed the development of the project data."
-end-
About LIAI

Founded in 1988, the La Jolla Institute for Allergy and Immunology is a nonprofit medical research center dedicated to increasing knowledge and improving human health through studies of the immune system. Scientists at the institute carry out research searching for cures for cancer, allergy and asthma, infectious diseases, and autoimmune diseases such as diabetes, inflammatory bowel disease and arthritis. LIAI's research staff includes more than 100 Ph.Ds.

La Jolla Institute for Allergy and Immunology

Related Immune System Articles from Brightsurf:

How the immune system remembers viruses
For a person to acquire immunity to a disease, T cells must develop into memory cells after contact with the pathogen.

How does the immune system develop in the first days of life?
Researchers highlight the anti-inflammatory response taking place after birth and designed to shield the newborn from infection.

Memory training for the immune system
The immune system will memorize the pathogen after an infection and can therefore react promptly after reinfection with the same pathogen.

Immune system may have another job -- combatting depression
An inflammatory autoimmune response within the central nervous system similar to one linked to neurodegenerative diseases such as multiple sclerosis (MS) has also been found in the spinal fluid of healthy people, according to a new Yale-led study comparing immune system cells in the spinal fluid of MS patients and healthy subjects.

COVID-19: Immune system derails
Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction - rather, the immune response is caught in a continuous loop of activation and inhibition.

Immune cell steroids help tumours suppress the immune system, offering new drug targets
Tumours found to evade the immune system by telling immune cells to produce immunosuppressive steroids.

Immune system -- Knocked off balance
Instead of protecting us, the immune system can sometimes go awry, as in the case of autoimmune diseases and allergies.

Too much salt weakens the immune system
A high-salt diet is not only bad for one's blood pressure, but also for the immune system.

Parkinson's and the immune system
Mutations in the Parkin gene are a common cause of hereditary forms of Parkinson's disease.

How an immune system regulator shifts the balance of immune cells
Researchers have provided new insight on the role of cyclic AMP (cAMP) in regulating the immune response.

Read More: Immune System News and Immune System Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.